The iconic rise of Sildenafil presented a massive opportunity for shareholders , but its patent has expired , creating a complex landscape. Generic versions have entered the market , cutting into revenues and putting a squeeze on profit yields. While major drug companies continue a presence in this field , the potential remains clouded by fierce ri